This Article  • Full text  • PDF  • Correction  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on ISI (3)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Randomized Controlled Trial  • Dermatologic Disorders, Other  • Phototherapy  • Alert me on articles by topic

Efficacy of Psoralen–UV-A Therapy vs Narrowband–UV-B Therapy

Sami Sasi Yones, Dip Der, MSc, FCD; Roy A. Palmer, MA, MRCP; Trish M. Garibaldinos, RN; John L. M. Hawk, MD, FRCP

Arch Dermatol. 2007;143(5):578-584.

Objective  To compare the efficacy of oral psoralen–UV-A (PUVA) with that of narrowband–UV-B (NB-UVB) phototherapy in patients with nonsegmental vitiligo.

Design  Double-blind randomized study.

Setting  Phototherapy unit in a university hospital.

Patients  Fifty-six patients with nonsegmental vitiligo.

Interventions  Twice-weekly therapy with PUVA or NB-UVB.

Main Outcome Measures  The change in body surface area affected by vitiligo and the color match of repigmented skin compared with unaffected skin were assessed after 48 sessions of therapy, at the end of the therapy course, and 12 months after the end of therapy.

Results  The results in the 25 patients each in the PUVA and NB-UVB groups who began therapy were analyzed. The median number of treatments was 47 in the PUVA-treated group and 97 in the NB-UVB–treated group (P = .03); we suspect this difference was because of the differences in efficacy and adverse effects between the 2 modalities, such that patients in the NB-UVB group wanted a longer course of treatment. At the end of therapy, 16 (64%) of 25 patients in the NB-UVB group showed greater than 50% improvement in body surface area affected compared with 9 (36%) of 25 patients in the PUVA group. The color match of the repigmented skin was excellent in all patients in the NB-UVB group but in only 11 (44%) of those in the PUVA group (P<.001). In patients who completed 48 sessions, the improvement in body surface area affected by vitiligo was greater with NB-UVB therapy than with PUVA therapy (P = .007). Twelve months after the cessation of therapy, the superiority of NB-UVB tended to be maintained.

Conclusion  In the treatment of nonsegmental vitiligo, NB-UVB therapy is superior to oral PUVA therapy.

Author Affiliations: Photobiology Unit, St John's Institute of Dermatology, Division of Genetics and Molecular Medicine, Guy’s, King's and St Thomas' School of Medicine, King's College, London, England.

RELATED ARTICLE

Vitiligo: To Treat or Not to Treat
Henry W. Lim and Camile L. Hexsel
Arch Dermatol. 2007;143(5):643-646.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Repigmentation in Vitiligo: PUVA vs. Narrowband UVB
Journal Watch Dermatology 2007;2007:1-1.
FULL TEXT  

Vitiligo: To Treat or Not to Treat
Lim and Hexsel
Arch Dermatol 2007;143:643-646.
FULL TEXT